BridgeBio Pharma (BBIO) Cash from Investing Activities (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -197.72% |
| Dec 31, 2025 | -421.55% |
| Sep 30, 2025 | 134.33% |
| Jun 30, 2025 | -715.17% |
| Mar 31, 2025 | 50.73% |
| Dec 31, 2024 | -108.47% |
| Sep 30, 2024 | 1,157.85% |
| Jun 30, 2024 | -86.64% |
| Mar 31, 2024 | 34,574.24% |
| Dec 31, 2023 | -100.18% |
| Sep 30, 2023 | 814.83% |
| Jun 30, 2023 | -66.51% |
| Mar 31, 2023 | -31.54% |
| Dec 31, 2022 | -87.77% |
| Sep 30, 2022 | -1.90% |
| Jun 30, 2022 | 7.99% |
| Mar 31, 2022 | 535.89% |
| Dec 31, 2021 | -63.03% |
| Sep 30, 2021 | 12,775.11% |
| Jun 30, 2021 | 100.16% |
| Mar 31, 2021 | -439.75% |
| Dec 31, 2020 | 284.28% |
| Sep 30, 2020 | 65.07% |
| Jun 30, 2020 | -439.23% |
| Mar 31, 2020 | 324.97% |
| Dec 31, 2019 | 91.44% |
| Sep 30, 2019 | -33,749.40% |
| Jun 30, 2019 | 75.98% |
| Mar 31, 2019 | 32.56% |
| Dec 31, 2018 | -494.88% |